10x Genomics, Inc. Class A Common Stock (TXG) Financials
Key financial figures for 10x Genomics, Inc. Class A Common Stock (Q2 2026).
10x Genomics Inc. reported revenue of $151.0 million for Q2 FY2026, down 12.6% from the same period a year earlier. The company posted a net loss of $17.9 million, or -$0.14 per share. Operating margin came to -12.95%, against 17.42% a year earlier. Free cash flow for the period was $15.4 million. Across the last 5 reported quarters, quarterly revenue has moved from $172.9 million in Q2 FY2025 to $151.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for 10x Genomics Inc. are on the SentiSense financials page.
- Revenue
- $151M
- Net Income
- -$18M
- EPS
- $-0.14
- Total Assets
- $1.0B
- Operating Cash Flow
- $17M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $151M | -$18M | -$0.14 | -12.95% | $15M |
| Q1 FY2026 | $151M | -$13M | -$0.10 | -11.3% | $25M |
| Q4 FY2025 | $166M | -$16M | -$0.13 | -11.77% | $39M |
| Q3 FY2025 | $149M | -$27M | -$0.22 | -21.64% | $43M |
| Q2 FY2025 | $173M | $35M | $0.28 | 17.42% | $16M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $643M | -$44M | -$0.35 | -17.25% | $130M |
| FY2024 | $611M | -$183M | -$1.52 | -31.85% | -$6M |
| FY2023 | $619M | -$255M | -$2.18 | -42.88% | -$65M |
Frequently asked questions
What was 10x Genomics Inc.'s revenue last quarter?
10x Genomics Inc. reported revenue of $151.0 million for Q2 FY2026, down 12.6% from the same period a year earlier.
Is 10x Genomics Inc. profitable?
Not in its most recent reported period. 10x Genomics Inc. reported a net loss of $17.9 million for Q2 FY2026, a net margin of -11.87% on revenue.
How has 10x Genomics Inc.'s margin trended?
Operating margin was -12.95% in Q2 FY2026, compared with 17.42% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did 10x Genomics Inc. generate?
10x Genomics Inc. generated free cash flow of $15.4 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for 10x Genomics, Inc. Class A Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.